Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

First head-to-head study of four United States (U.S.) Food & Drug Administration (FDA) approved neurotoxins: Jeuveau®, Botox®, Dysport®, and Xeomin® The study published in JAMA Dermatology